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AN apparent discrepancy exists between the multiplicity of experimental
cancer cures which have appeared in the literature since homologous transmission
oftumours was first demonstrated, and the difficulties encountered in the therapy
of human cancer. Among the basic reasons for this are differences in the host-
tumour relationship which presents a range of characteristics, from the com-
pletely unstable heterologous relationship, where the host and tumour are of
different strains, or even species, to the relatively stable situation, as with human
or other autogenous tumours. Between these two extremes are the many, now
widely used, homologous tumours displaying varying degrees of stability. The
facile experimental cure, or spontaneous regression of a tumour followed by
absolute immunity to further implants, is invariably a feature of the relatively
unstable host-tumour relationship, and the less stable this relationship the more
effective the " cure," be it mechanical, chemical or radiological. Since this
propitious situation rarely, ifever, occurs in humans bearing autogenous tumours,
experimental investigation of an animal tumour can have at best only remote
application to clinical cancer therapy unless it applies in the first instance to a
stable host-tumour relationship. As a prerequisite to any such investigation,
therefore, the following criteria for stability of the host-tumour relationship are
considered indispensable:
(1) There shall be unequivocal evidence of malignancy, characterised by
progressive growth, invasion or metastasis, and death ofthe host.
(2) The tumour shall be genetically compatible with the host, either having
arisen spontaneously or been induced in the tissues of the animal being investi-
gated, or be transmitted by implantation into a homologous animal closely
related by inbreeding to the host in which the tumour first arose.
(3) The tumour shall " take " in practically 100 per cent of recipients on
irnplantation, and there shall be neither spontaneous regression nor regression
induced by non-specific trauma or intoxication ofthe host.
(4) On irradiation ofthe tumour in situ, the curative dose shall be ofthe same
order of magnitude as that of human tumours (103 to 104 r).
(5) Removal or destruction of the tumour in situ shall not evoke absolute
resistanoe to further implants ofthe same tumour.
Since both human and experimental arLimal tumours can be made to regress
following exposure to ionising radiations, one of the more promising avenues ofA. COHEN AND L. COHEN
research would appear to be the investigation of all factors affecting the radio-
sensitivity oftumours. Although earlier work in this field has formulated certain
fundamental principles (Krebs, 1929; Cramer, 1932; Crabtree and Cramer,
1934; Sugiura, 1937; Sugiura and Cohen, 1939; Goldfeder, 1942), it has been
largely limited by inaccurate dosage estimation or lack of suitable biologic
materials. It is now possible for the radiobiologist to combine precise quantita-
tive radiotherapy with a judicious choice of experimental hosts and tumours;
and it was with this in mind that a study of the radiobiology of the C3H mouse
mammary adenocarcinoma was undertaken. The growth characteristics of this
tumour, including data on its radiosensitivity, have been reported by Goldfeder
(1950, 1951). Her dosage data are, however, associated with a large standard
error, the coefficient of variation approaching 65 per cent for irradiation in situ,
which can probably be ascribed to irregularities in absorption and scatter rather
than to intrinsic variation among the animals. In the following experiments
a more precise dosimetric technique, permitting the determination of median
lethal doses within much narrower limits, is described, the eventual purpose of
which is to detect and measure any changes in radiosensitivity that might be
induced by an experimental procedure.
MATERIALS AND METHODS.
Animals.
Some preliminary studies were done on a C3H subline generously donated by
Professor A. Haddow of the Chester Beatty Institute, London. This group even-
tually succumbed to infection and died out. The mice used in this investigation
are descendants of an original group of 30 C3H mice imported from the Roscoe B.
Jackson Memorial Laboratory, Bar Harbor, Maine, and maintained on the
standard laboratory chow diet with tap water ad libitum. The incidence of
spontaneous mammary adenocarcinoma among females is high. For trans-
mission, the tumour-bearing mouse was anaesthetised with intraperitoneal sodium
pentobarbital (.06 lig. per g. body weight), the tumour removed aseptically
minced with a fine scissors and inoculated subcutaneously into the axilla or
flank of recipients of mixed sexes weighing 20 to 25 g. by means of a trocar and
cannula. Although spontaneous tumours were frequently used for routine
passage, only well-established homoplasts were transmitted to animals in the
experimental groups. In general, on implantation of a fragment (about 1 mm.3
in size) a nodule becomes palpable (measuring about 4 mm.3) after a latent period
of 7 to 15 days, and grows exponentially approximately doubling its volume
every 4 to 5 days.
Radiationfactors.
Physical conditions for these experiments were kept constant as far as possible
throughout the investigation. The radiation was generated by a G.E. " Maxi-
mar " self-rectified unit, at 240 kVp. with no added filters (the inherent filtration
of the tube-head consisting of approximately 3 mm. oil and 1 mm. bakelite in
addition to the glass envelope), giving a half-value layer of 0 34 mm. Cu. At an
F.S.D. of 25 cm. the dose rate was 500 r/min. (± 3 per cent ) measured in air.
Dose rates were measured in air with a secondary standard (Victoreen) dosemeter,
and corrected for atmospheric density. When necessary, the back-scatter and
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absorption factors relevant to this quality of radiation (obtained from Quimby
and Laurence's technical bulletin, 1940), were introduced. The atmospheric
temperature and pressure in this laboratory (altitude 1800 metres) remained
reasonably constant at 21 (± 3)0 C. and 625 (± 5) mm. Hg, so that any change
in radiosensitivity or biological effects possibly attributed to variation in oxygen
tension could be evaluated if relevant differences were detected in other centres.
For treatment in situ the mouse was anaesthetised with intraperitoneal
sodium pentobarbital, the tumour retracted from the mouse's body on to a wax
slab by means of a haemostat grasping the overlying hair, and a 2 cm. diameter
circular applicator applied directly over the tumour nodule (Fig. 1). The wax
backing ensures that back-scatter remains constant even though the tumour
only partially fills the treated field. In practice, absorption in the mass of these
small tumours just about offsets the effect of back-scatter so that a negligible
Wax.
Lead-
FiG. 1.-Method of treating tumours in 8itu. The mouse's body is completely
protected by lead from scattered radiation.
error is introduced by measuring tumour doses in terms ofdose-rate in air. It has
also been found necessary to screen the mouse during treatment from scattered
radiation, which otherwise can deliver a body dose approaching 20 r/min. The
2 mm. lead screens shown (Fig. 1) effectively reduce the body dose to less than
2 r/min. (0.4 per cent ofthe tumour dose). Since, however, the volume oftumour
treated averages about 500 mm.3 (2 per cent of the body weight), there is an
unavoidable systemic effect equivalent to a body dose of about 2 per cent of the
given tumour dose, a quantity which may affect the resistance ofthe host.
For irradiation prior to implantation, minced tumour fragments were placed
in a welled plastic (methacrylate) slide recessed into a hard-wood block and
covered with a thin plastic cover-slip sealed in place with low melting-point
paraffin wax. The " well " forms a circular cavity 18 mm. in diameter and 1 mm.
in depth, with a rounded floor matching a concave isodose surface. When com-
pletely filled with tissue fragments this arrangement provides full back-scatter
for the field used, and avoids any heterogeneity due to variations in density or
atomic number such as would be encountered with a glass slide. A 5 cm. field is
centered over the tissue, which then receives almost completely homogeneous
irradiation, including a back-scatter contribution of 20 per cent, at a dose rate of
600 r/min.
233A. COHEN AND L. COHEN
Experimental design.
Not less than three groups of 10 to 20 animals in each of the various experi-
mental categories were treated with graded doses of radiation in the form of a
geometric series, each successive group receiving a dose roughly 20 per cent
greater than its predecessor. Within each experimental category the median
effective dose (LD50), and the variance among individual animals, were estimated
graphically on the basis of a three-dose log-probit design (Fig. 2). The standard
errors of the median and of the slope of the dosage-response line could then be
obtained from the graph after the method of Litchfield and Fertig (1941).
Dose(r)
FIG. 2.-Parallel dosage-response lines on log-probit co-ordinates showing (A) percentage
regression v. dose for irradiation in vivo, and (B) percentage non-takes v. dose for irradiation
of tumour before inoculation.
RESULTS.
In Table I the response of the C3H adenocarcinoma to treatment in situ at
three dosage levels is shown. The tumour is relatively radioresistant, requiring
doses of the order of 6000 r in one treatment to produce a significant number of
regressions. This is essentially similar to Goldfeder's findings (1951). With the
technique described there were no marginal recurrences, and provided that the
tumour was not close to the abdomen, no radiation sickness was observed, nor
was there any immediate post-irradiation mortality. At these doses the skin
of the mouse reacts briskly to the point of moist desquamation, but eventually
heals, leaving a patch of white hair in the treated area.
TABLE I.-Treatment ofthe C3H Adenocarcinoma in situ.
Regression "Takes"
Dose Number Number Cures time on
(r). of mice. cured. %. (av.) re-inocu-
(days). lation.
7500 . 13 . 13 . 100 . 29 . 3/3
6000 . 13 . 10 . 77 . 46 . 9/9
5000 . 13 . 1 . 8 . 98* . 1/1
* See text for discussion.
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At the borderline " sublethal " dose of 5000 r some of the tumours regressed
to small static nodules, which were still present and palpable several months
after treatment. This phenomenon was previously observed in tumour-bearing
animals by Cramer (1934). For the purpose of this study such nodules are
categorised as persistent tumour, since a proportion of them eventually resumed
growth, and all showed apparently viable cells on histological examination.
Several autogenous tumours were also treated in situ, but are not tabulated.
Their curability paralleled that ofthe homoplasts in that they could be eradicated
with 7500 r and did not respond fully to 5000 r. However, certain difficulties
arise in evaluating results in the case of autogenous tumours, since these mice
are usually old and poor anaesthetic risks, the tumours are usually multiple and
often fixed in inaccessible areas, and in many cases lung metastases are present
at the time oftreatment or develop shortly afterwards.
The results of attenuation by irradiating the tumour prior to implantation
are shown in Table II. It will be noted that a relatively small dose ofradiation,
about halfthat required to cure it in situ, will prevent the tumour from " taking."
TABLE II.-Attenuation Doses of the C3H Mammary Carcinoma
Prior to Implantation.
Average "Takes"
Dose Number Number Non-takes latent on
(r). of mice. "takes" % period. re-inocu-
(days). lation.
3500 . 15 . 0 . 100 . .. . 15/15
3000 . 20 . 5 . 75 . 59 . 9/9
2500 . 23 . 22 . 4 . 35
2000 . 10 . 10 . 0 . 30
This attenuation dose is higher than that reported by Goldfeder (1947) for
the same tumour. The discrepancy is- probably due to ionisation contributed
by the glass slide in which her tumour fragments were irradiated, instead of the
plastic used in this experiment. It is ofinterest to note that the effective dosage
for some other strains ofmouse mammary carcinomas irradiated prior to implanta-
tion are of a similar magnitude (Lawrence, Horn and Strong, 1937; Reinhard,
Goltz and Warner, 1952). Considering that their more heavily filtered radiation
(HVL 1 mm. Cu.) has a relative biological efficiency of about four-fifths of that
used in this experiment, the reported effective dosage of 3600 r is virtually
identical with our findings.
The results of both types of irradiation are analysed graphically in Fig. 2
using the " probit " method, from which it can be deduced that, in the case of
treatment in situ (line A) the LD50 is 5700 (+ 140*) r, and for attenuation prior
to implantation (line B) the LD50 is 2850 (i 50*) r. It will be noted that the
two dosage-response lines are apparently parallel, their slopes corresponding in
both cases to a coefficient ofvariation ofabout 9 per cent.
Attenuation of tumour homoplasts by X rays prior to implantation into
animals was described as early as 1909 by Haaland. On occasion, this procedure
was shown to induce a state in which the recipient became resistant to challenge
with unirradiated implants of the same tumour, although rarely were adequately
inbred strains immunised against homologous carcinoma (Hauschka, 1952). As
* Standard error of median.
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can be seen in Tables I and II, most animals cured of a previous tumour or found
to be resistant to attenuated fragments were challenged with subsequent tumour
implants. In contrast to Goldfeder's (1950) findings, these re-inoculations
"took " in all cases.
The re-inoculated tumour nodules were then irradiated at three dosage levels,
and the results show no significant difference in response between these tumours
and those in control animals (Table III).
TABLE III.-Treatment of the C3H Adenocarcinoma in situ in Hosts Previously
Cured ofTumour or Inoculated with Attenuated Fragments that did not" Take."
Dose Number . Number Cures
(r). of mice. cured. 00.
F 4 Tumour cured with 6000. 1 )
| ~~~r. Re-inoculated.l
5000 4 Inoculated with fragment . 2
attenuated at 3000 r




. Inoculated withfragment 1
attenuated at 3000 r
that did not " take." 6
Re-inoculated.
7000 . 3 .Turnour cured with 6000 . 3
r. Re-inoculated. J
Although 3 cures out of 8 mice treated with 5000 r appears to differ from
expectation (p _ .05), it must be borne in mind that this is a selected group of
mice chosen from among those already cured and relatively resistant to attenuated
tumour. It can be concluded, therefore, that the previous treatments did not
significantly influence the subsequent behaviour of the tumour, there being no
appreciable increase or decrease in radiosensitivity of the re-inoculated tumours
as a result of the previous manipulations. It appears that the homologously
transmitted C3H adenocarcinoma resembles autogenous human tumours in that
neither will elicit obvious immunity by such facile procedures as X ray-induced
regression in situ or injection of radiation-attenuated tumour fragments.
SUMMARY.
As a preliminary to an investigation into the role of the host-tumour relation-
ship in determining the radiosensitivity of tumours, the response of the C3H
mammary adenocarcinoma to X rays was measured by precise dosimetric
techniques, and analysed by the probit method. The LD50 for the treatment of
the tumour in situ was found to be 5700 (+ 140) r, and the LD50 for attenuation
prior to implantation was 2850 (± 50) r. Animals cured of tumour, and those
resistant to radiation-attenuated implants, showed no resistance to a subsequent
challenge with a second inoculum.
All the necessary facilities for the isolation, breeding and maintenance of the
inbred mice used in this investigation were most generously provided by Dr.
J. F. Murray and Dr. J. H. S. Gear, Deputy-Directors of the South African
Institute for Medical Research, to whom we are deeply indebted.
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